Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice

  • Verberk, I.M.W.
  • Jutte, J.
  • Kingma, M.Y.
  • Vigneswaran, S.
  • Gouda, M.M.T.E.E.
  • van Engelen, M.P.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Chevalier, C.
  • Marizzoni, M.
  • van de Giessen, E.M.
  • Lemstra, A.W.
  • Pijnenburg, Y.A.L.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • den Braber, A.
  • Wilson, D.
  • Schut, M.C.
  • van Harten, A.C.
  • Teunissen, C.E.
INTRODUCTION: We developed a multimarker blood test result interpretation tool for the clinical dementia practice, including phosphorylated (P-)tau181, amyloid-beta (Abeta)42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). METHODS: We measured the plasma biomarkers with Simoa (n = 1199), applied LASSO regression for biomarker selection and receiver operating characteristics (ROC) analyses to determine diagnostic accuracy. We validated our findings in two independent cohorts and constructed a visualization approach. RESULTS: P-tau181, GFAP, and NfL were selected. This combination had area under the curve (AUC) = 83% to identify amyloid positivity in pre-dementia stages, AUC = 87%-89% to differentiate Alzheimer's or controls from frontotemporal dementia, AUC = 74%-76% to differentiate Alzheimer's or controls from dementia with Lewy bodies. Highly reproducible AUCs were obtained in independent cohorts. The resulting visualization tool includes UpSet plots to visualize the stand-alone biomarker results and density plots to visualize the biomarker results combined. DISCUSSION: Our multimarker blood test interpretation tool is ready for testing in real-world clinical dementia settings. Highlights: We developed a multimarker blood test interpretation tool for clinical dementia practice. Our interpretation tool includes plasma biomarkers P-tau, GFAP, and NfL. Our tool is particularly useful for Alzheimer's and frontotemporal dementia diagnosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment

  • Bolsewig, K.
  • Willemse, E.A.J.
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Rábano, Alberto|||0000-0001-9320-6566
  • Martínez, Minerva|||0000-0002-9036-2595
  • Doecke, J.D.|||0000-0003-2863-0293
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Vermunt, L.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Halbgebauer, S.
  • in 't Veld, S.
  • Mattsson-Carlgren, N.
  • Veverova, K.
  • Fowler, C.J.
  • Boonkamp, L.
  • Koel-Simmelink, M.
  • Hussainali, Z.
  • Ruiters, D.N.
  • Gaetani, L.
  • Toja, A.
  • Fortea, Juan|||0000-0002-1340-638X
  • Pijnenburg, Y.
  • Lemstra, A.W.
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Hort, J.
  • Otto, M.|||0000-0003-4273-4267
  • Hansson, Oskar|||0000-0001-8467-7286
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Masters, C.L.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Teunissen, C.E.
  • Campo Milán, Marta del|||0000-0003-2808-3699
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson's disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Hepcidin as a potential informative biomarker of Alzheimer disease and vascular dementia

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Busto, G.
  • Gabelle, A.
  • Ayrignac, X.
  • Bennys, K.
  • Muiño, Elena|||0000-0001-5839-7328
  • Villatoro-González, Paula|||0009-0001-0287-4073
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Pradeilles, N.
  • Bounasri, Shaima El
  • Torres Alcalá, Soraya|||0000-0002-7054-2046
  • Hirtz, C.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Lehmann, Sylvain|||0000-0001-6117-562X
Background: Blood-based assays are expected to be integrated into clinical routines across various contexts, including Alzheimer's disease (AD). Vascular dementia (VaD), which is the second most common cause leading to dementia after AD, could also significantly benefit from this advancement. However, no informative fluid biomarker has been identified for VaD. Given the disruption of iron homeostasis in both AD and VaD, this study aims to characterize the potential of the iron-related hormone Hepcidin as a biomarker for these two conditions. We will compare its added value to established AT(N) blood biomarkers. Methods: Blood biomarkers (amyloid-composite, p-Tau, Neurofilament Light Chain [NfL] and Hepcidin) levels in blood were analyzed in two independent cohorts and compared between AD patients and non-AD individuals. Additionally, blood Hepcidin and NfL were evaluated in the contexts of VaD and CADASIL, with their relative diagnostic value assessed. Results: Blood Hepcidin and NfL do not significantly increase the AUC obtained with both p-Tau and amyloid composite in the context of AD. In contrast, AUC for VaD diagnosis is significantly higher when combining these two blood biomarkers compared to NfL alone. Hepcidin was not significantly modified in CADASIL patients compared to control subjects. Conclusion: Blood Hepcidin and NfL have limited interest in the clinical context of AD but determination of these biomarkers shows to be highly informative for the diagnosis of VaD. This result could have important implications for diagnosis and implementation of clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients

  • Hok-A-Hin, Yanaika S.|||0000-0001-9713-116X
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Barkhof, Frederik|||0000-0003-3543-3706
  • del Campo, Marta
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Vermunt, Lisa
  • Oosthoek, Marlies
  • Vijverberg, Everard G.B.
  • Blujdea, Elena R.
  • Veld, Sjors G.J.G.In't
  • Pucheu Avilés, Martín
  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Visser, Allerdien
  • Schut, Martijn C.
Background: Amyloid-related imaging abnormalities (ARIA) are a common and potentially dangerous side effect in anti-amyloid therapies, creating a need for tools to assess ARIA risk. Several patient factors have been linked to ARIA; namely the presence of microbleeds (MBL), APOE E4 carriership (APOE4), and extremely low CSF Aβ42 concentrations (A). We hypothesize that studying the CSF proteome of Alzheimer's disease (AD) dementia patients from a high-risk group (MBLAPOE4A) can inform on the biological underpinnings of ARIA risk and aid the progress of ARIA risk biomarkers. Methods: We utilized CSF proteomic data of AD (n = 156) and cognitively unimpaired individuals (CU n = 100) of the Amsterdam Dementia Cohort. The proteome of the defined high-risk (n = 13) was compared to low-risk AD group (n = 23), using age and sex corrected linear regressions followed by gene ontology analysis. For biomarker prioritization, we selected proteins that were abnormal in the high-risk group versus low-risk and CU patients. The biomarkers were validated in an independent cohort (high risk n = 14, low risk n = 9) analyzed using customized multiplex panels. Lastly, we assessed biomarker lead co-expression. Results: Ninety-four proteins differentiated in the high-risk group compared to low-risk (p < 0.05), none surviving FDR correction. These proteins were enriched for synapse-related proteins and axonogenesis. CHIT1 (vs. low-risk AD: FC = 1.0, p = 0.014, vs. CU: FC = 2.4, p < 0.001) and DDAH1 (vs. low-risk AD: FC=-0.31, p = 0.046, vs. CU: FC = 0.5, p < 0.001) were prioritized as biomarker. DDAH1 protein changes replicated in an independent cohort (FC=-0.37, p = 0.010), and CHIT1 replicated on a trend level (FC = 0.70, p = 0.104). DDAH1 levels had the highest co-expression with synaptic process, energy utilization and RNA-binding cell signaling related proteins (R > 0.8). Conclusions: The findings suggest that in the high risk group, there is a lack of upregulation in synapse and axonogenesis related proteins. High CSF CHIT1 and less increased CSF DDAH1 levels within AD relate to ARIA risk. From the literature, the link to ARIA risk for CHIT1 could be its contribution to innate immunity or vascular amyloid deposition, and for DDAH1 to blood-brain barrier integrity. Biomarker assays are available to assess the potential of CHIT1 and DDAH1 in trials and treatment studies in the clinical setting.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

  • Janelidze, Shorena
  • Therriault, Joseph
  • Brum, Wagner S.
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Stomrud, Erik
  • Palmqvist, Sebastian|||0000-0002-9267-1930
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Rahmouni, Nesrine
  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Blennow, Kaj|||0000-0002-1890-4193
  • Doré, Vincent
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Villeneuve, Sylvia
  • Johnson, Sterling C.
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Petersen, Ronald C.
  • Schindler, Suzanne E.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Ossenkoppele, Rik
  • Hansson, Oskar|||0000-0001-8467-7286
  • Salvadó, Gemma
  • Bali, Divya
  • Orduña Dolado, Anna
  • Mattsson-Carlgren, Niklas
  • Coomans, Emma M.
  • Benzinger, Tammie L. S.
  • Feizpour, Azadeh
  • Rowe, Christopher C.
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ϵ4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P =.12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P <.001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P <.001). Conclusions and Relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test - or when used in a sequential 2-step approach alongside PET or CSF testing - as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments..
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer's disease cerebrospinal fluid

  • Lleó, Alberto|||0000-0002-2568-5478
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Chiva, Cristina
  • Balateu Paños, Daniel
  • Colom-Cadena, Martí|||0000-0002-8514-4534
  • Gómez, Gemma
  • Muñoz, Laia|||0000-0003-0578-3094
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Tainta, Mikel|||0000-0003-0624-1211
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Spires Jones, Tara
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Martínez Lage, Pablo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Bayés, Àlex|||0000-0002-5265-6306
  • Belbin, Olivia|||0000-0002-6109-6371
A biomarker of synapse loss, an early event in Alzheimer's disease (AD) pathophysiology that precedes neuronal death and symptom onset, would be a much-needed prognostic biomarker. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins. In this study, we aimed to identify and validate novel CSF biomarkers of synapse loss in AD. Discovery: Combining shotgun proteomics of the CSF with an exhaustive search of the literature and public databases, we identified 251 synaptic proteins, from which we selected 22 for further study. Verification: Twelve proteins were discarded because of poor detection by Selected Reaction Monitoring (SRM). We confirmed the specific expression of 9 of the remaining proteins (Calsyntenin-1, GluR2, GluR4, Neurexin-2A, Neurexin-3A, Neuroligin-2, Syntaxin-1B, Thy-1, Vamp-2) at the human synapse using Array Tomography microscopy and biochemical fractionation methods. Exploration: Using SRM, we monitored these 9 synaptic proteins (20 peptides) in a cohort of CSF from cognitively normal controls and subjects in the pre-clinical and clinical AD stages (n 80). Compared with controls, peptides from 8 proteins were elevated 1.3 to 1.6-fold (p < 0.04) in prodromal AD patients. Validation: Elevated levels of a GluR4 peptide at the prodromal stage were replicated (1.3-fold, p 0.04) in an independent cohort (n 60). Moreover, 7 proteins were reduced at preclinical stage 1 (0.6 to 0.8-fold, p < 0.04), a finding that was replicated (0.7 to 0.8-fold, p < 0.05) for 6 proteins in a third cohort (n 38). In a cross-cohort meta-analysis, 6 synaptic proteins (Calsyn-tenin-1, GluR4, Neurexin-2A, Neurexin-3A, Syntaxin-1B and Thy-1) were reduced 0.8-fold (p < 0.05) in preclinical AD, changes that precede clinical symptoms and CSF markers of neurodegeneration. Therefore, these proteins could have clinical value for assessing disease progression, especially in preclinical stages of AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Conway, Olivia J.
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Carrasquillo, Minerva M.
  • Kleineidam, Luca
  • van den Akker, Erik
  • Hernández, Isabel|||0000-0001-8119-393X
  • Van Eijk, Kristel R.
  • Stringa, Najada|||0000-0001-6350-452X
  • Chen, Jason A.
  • Zettergren, Anna|||0000-0002-7182-8417
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Simón Sánchez, Javier|||0000-0001-5141-5829
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Nygaard, Marianne|||0000-0003-0703-2665
  • Blauwendraat, Cornelis|||0000-0001-9358-8111
  • Savage, Jeanne E.
  • Mengel-From, Jonas
  • Moreno-Grau, Sonia
  • Wagner, Michael
  • Fortea, Juan|||0000-0002-1340-638X
  • Keogh, Michael J.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Skoog, Ingmar
  • Friese, Manuel A.
  • Pletnikova, Olga|||0000-0001-6516-4944
  • Zulaica, Miren
  • Lage, Carmen|||0000-0003-1703-121X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Wei, Wei
  • Jeune, Bernard
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Then Bergh, Florian
  • Wang, Xue
  • Hulsman, Marc|||0000-0002-9889-3606
  • Beker, Nina
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Morris, Christopher M.
  • Indakoetxea, Begoña
  • Collij, Lyduine E.
  • Scherer, Martin
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Ironside, James W.
  • van Berckel, Bart N. M.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Strickland, Samantha L.
  • Pastor, Pau|||0000-0002-7493-8777
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Boeve, Bradley
  • Petersen, Ronald C.
  • Ferman, Tanis J.
  • van Gerpen, Jay A.
  • Reinders, Marcel J. T.|||0000-0002-1148-1562
  • Uitti, Ryan J.
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Maier, Wolfgang
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Kawalia, Amit
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Boada, Mercè|||0000-0003-2617-3009
  • Zettl, Uwe K.
  • van Schoor, Natasja M.
  • Beekman, Marian|||0000-0003-0585-6206
  • Allen, Mariet
  • Masliah, Eliezer
  • de Munain, Adolfo López
  • Pantelyat, Alexander
  • Wszolek, Zbigniew K.|||0000-0001-5487-1053
  • Ross, Owen A.|||0000-0003-4813-756X
  • Dickson, Dennis W.|||0000-0001-7189-7917
  • Graff-Radford, Neill R.
  • Knopman, David
  • Rademakers, Rosa
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gasser, Thomas|||0000-0003-4882-2647
  • Chinnery, Patrick F.
  • Hemmer, Bernhard|||0000-0001-5985-6784
  • Huisman, Martijn A.
  • Troncoso, Juan
  • Moreno, Fermin|||0000-0001-5200-3164
  • Nohr, Ellen A.
  • Sørensen, Thorkild I. A.|||0000-0003-4821-430X
  • Heutink, Peter|||0000-0001-5218-1737
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Christensen, Kaare|||0000-0002-5429-5292
  • Ertekin-Taner, Nilüfer
  • Scholz, Sonja|||0000-0002-6623-0429
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Slagboom, Eline
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Holstege, Henne|||0000-0002-7688-3087
The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLCγ2 pathway as drug-target.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

  • Alcolea, Daniel|||0000-0002-3819-3245
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Muñoz, Laia|||0000-0003-0578-3094
  • Camacho, Valle|||0000-0003-0748-0847
  • Lopez Mora, Diego Alfonso|||0000-0002-3533-7362
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Le Bastard, Nathalie
  • Huyck, Else
  • Nadal, Alicia
  • Olmedo, Verónica
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
To determine the cutoffs that optimized the agreement between 18 F-Florbetapir positron emission tomography (PET) and A β 1-42, A β 1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18 F-Florbetapir imaging. Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of A β 1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18 F-Florbetapir PET and evaluated concordance between markers of the amyloid category. A β 1-42, tTau and pTau (but not A β 1-40) and the ratios with A β 1-42 had good diagnostic agreement with 18 F-Florbetapir PET. As a marker of amyloid pathology, the A β 1-42/A β 1-40 ratio had higher agreement and better correlation with amyloid PET than A β 1-42 alone. CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of A β 1-42 with A β 1-40 increases the agreement between markers of amyloid pathology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sex-dependent calcium hyperactivity due to lysosomal-related dysfunction in astrocytes from APOE4 versus APOE3 gene targeted replacement mice

  • Larramona Arcas, Raquel|||0000-0001-8427-8007
  • González-Arias, Candela
  • Perea, Gertrudis
  • Gutiérrez Pérez, Antonia|||0000-0002-6264-6152
  • Vitorica, Javier
  • García-Barrera, Tamara
  • Gómez-Ariza, José Luis
  • Pascua-Maestro, Raquel
  • Ganfornina, María Dolores
  • Kara, Eleanna
  • Hudry, Eloise
  • Martinez-Vicente, Marta|||0000-0001-7053-2625
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Galea, Elena|||0000-0003-4537-9897
  • Masgrau Juanola, Roser|||0000-0002-6722-5939
The apolipoprotein E (APOE) gene exists in three isoforms in humans: APOE2, APOE3 and APOE4. APOE4 causes structural and functional alterations in normal brains, and is the strongest genetic risk factor of the sporadic form of Alzheimer's disease (LOAD). Research on APOE4 has mainly focused on the neuronal damage caused by defective cholesterol transport and exacerbated amyloid-β and Tau pathology. The impact of APOE4 on non-neuronal cell functions has been overlooked. Astrocytes, the main producers of ApoE in the healthy brain, are building blocks of neural circuits, and Ca 2+ signaling is the basis of their excitability. Because APOE4 modifies membrane-lipid composition, and lipids regulate Ca 2+ channels, we determined whether APOE4 dysregulates Ca 2+ signaling in astrocytes. Ca 2+ signals were recorded in astrocytes in hippocampal slices from APOE3 and APOE4 gene targeted replacement male and female mice using Ca 2+ imaging. Mechanistic analyses were performed in immortalized astrocytes. Ca 2+ fluxes were examined with pharmacological tools and Ca 2+ probes. APOE3 and APOE4 expression was manipulated with GFP- APOE vectors and APOE siRNA. Lipidomics of lysosomal and whole-membranes were also performed. We found potentiation of ATP-elicited Ca 2+ responses in APOE4 versus APOE3 astrocytes in male, but not female, mice. The immortalized astrocytes modeled the male response, and showed that Ca 2+ hyperactivity associated with APOE4 is caused by dysregulation of Ca 2+ handling in lysosomal-enriched acidic stores, and is reversed by the expression of APOE3, but not of APOE4, pointing to loss of function due to APOE4 malfunction. Moreover, immortalized APOE4 astrocytes are refractory to control of Ca 2+ fluxes by extracellular lipids, and present distinct lipid composition in lysosomal and plasma membranes. Immortalized APOE4 versus APOE3 astrocytes present: increased Ca 2+ excitability due to lysosome dysregulation, altered membrane lipidomes and intracellular cholesterol distribution, and impaired modulation of Ca 2+ responses upon changes in extracellular lipids. Ca 2+ hyperactivity associated with APOE4 is found in astrocytes from male, but not female, targeted replacement mice. The study suggests that, independently of Aβ and Tau pathologies, altered astrocyte excitability might contribute to neural-circuit hyperactivity depending on APOE allele, sex and lipids, and supports lysosome-targeted therapies to rescue APOE4 phenotypes in LOAD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome

  • Lleó, Alberto|||0000-0002-2568-5478
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Fernández, Susana|||0000-0002-9777-1156
  • Benejam, Bessy|||0000-0002-6789-8615
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Xiao, Mei-Fang
  • Xu, Desheng
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Worley, Paul
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Belbin, Olivia|||0000-0002-6109-6371
There is an urgent need for objective markers of Alzheimer's disease (AD)-related cognitive impairment in people with Down syndrome (DS) to improve diagnosis, monitor disease progression, and assess response to disease-modifying therapies. Previously, GluA4 and neuronal pentraxin 2 (NPTX2) showed limited potential as cerebrospinal fluid (CSF) markers of cognitive impairment in adults with DS. Here, we compare the CSF profile of a panel of synaptic proteins (Calsyntenin-1, Neuroligin-2, Neurexin-2A, Neurexin-3A, Syntaxin-1B, Thy-1, VAMP-2) to that of NPTX2 and GluA4 in a large cohort of subjects with DS across the preclinical and clinical AD continuum and explore their correlation with cognitive impairment. We quantified the synaptic panel proteins by selected reaction monitoring in CSF from 20 non-trisomic cognitively normal controls (mean age 44) and 80 adults with DS grouped according to clinical AD diagnosis (asymptomatic, prodromal AD or AD dementia). We used regression analyses to determine CSF changes across the AD continuum and explored correlations with age, global cognitive performance (CAMCOG), episodic memory (modified cued-recall test; mCRT) and CSF biomarkers, CSF Aβ ratio, CSF Aβ, CSF p-tau, and CSF NFL. P values were adjusted for multiple testing. In adults with DS, VAMP-2 was the only synaptic protein to correlate with episodic memory (delayed recall adj.p =.04) and age (adj.p =.0008) and was the best correlate of CSF Aβ (adj.p =.0001), p-tau (adj.p < .0001), and NFL (adj.p < .0001). Compared to controls, mean VAMP-2 levels were lower in asymptomatic adults with DS only (adj.p =.02). CSF levels of Neurexin-3A, Thy-1, Neurexin-2A, Calysntenin-1, Neuroligin-2, GluA4, and Syntaxin-1B all strongly correlated with NPTX2 (p <.0001), which was the only synaptic protein to show reduced CSF levels in DS at all AD stages compared to controls (adj.p <.002). These data show proof-of-concept for CSF VAMP-2 as a potential marker of synapse degeneration that correlates with CSF AD and axonal degeneration markers and cognitive performance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone

  • Estellés, Teresa
  • Zhu, Nuole|||0000-0002-0015-9455
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Subirana, Andrea
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Belbin, Olivia|||0000-0002-6109-6371
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes. To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression. We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as "positive" or "negative" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models. In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs. Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD. The online version contains supplementary material available at 10.1186/s13195-022-00967-z.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

  • Zhu, Nuole|||0000-0002-0015-9455
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Estellés, Teresa
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Muñoz, Laia|||0000-0003-0578-3094
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer's disease (AD) and their clinical utility in predicting disease progression. Methods: pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results: Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions: pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.